BioCentury
ARTICLE | Clinical News

ACE-083: Ph II started

January 12, 2017 12:41 AM UTC

Acceleron began a U.S. Phase II trial to evaluate 150, 200 and 250 mg intramuscular ACE-083 given 3 weeks apart for up to 5 doses in patients with muscle weakness in the bicep or tibialis anterior. An...

BCIQ Company Profiles

Acceleron Pharma Inc.

BCIQ Target Profiles

Myostatin (MSTN) (GDF8)